Stock Price, News, Quote and Profile of FULGENT GENETICS INC(NASDAQ:FLGT) stock

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

FULGENT GENETICS INC

NASDAQ:FLGT (5/3/2024, 7:00:00 PM)

After market: 21.5 0 (0%)

21.5

+0.26 (+1.22%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryHealth Care Providers & Services

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Overview

Earnings (Last)

Earnings (Next)

Ins Owners

Inst Owners

Market Cap642.85M

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts

IPO

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Fulgent Genetics, Inc. is a technology company, which engages in the provision of gene testing and sequencing solutions. The company is headquartered in El Monte, California and currently employs 1,012 full-time employees. The company went IPO on 2016-09-28. The firm's clinical diagnostic business offers molecular diagnostic testing services, genetic testing, and anatomic pathology laboratory services designed to provide physicians and patients with clinically actionable diagnostic information. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile (PK) profile of new and existing cancer drugs. Its business is built on its technology platform, which includes gene probes, data suppression and comparison algorithms, learning software, and laboratory information management systems. The firm's technology platform offers a test menu. The firm also offers next-generation sequencing (NGS) services.